Pricing
  1. US-listed companies
  2. HALOZYME THERAPEUTICS, INC.
  3. Financials
  4. D/E ratio (%)

HALOZYME THERAPEUTICS, INC. (HALO)

Market cap
$7.9B
P/E ratio
SummaryFinancials
Period EndD/E ratio (%) (Million USD)YoY (%)
Dec 31, 2024413.9-76.86%
Dec 31, 20231,788.9+101.68%
Dec 31, 2022887+99.27%
Dec 31, 2021445.1+69.26%
Dec 31, 2020263-40.06%
Dec 31, 2019438.7+763.99%
Dec 31, 201850.8-47.71%
Dec 31, 201797.1-114.56%
Dec 31, 2016-666.9-675.46%
Dec 31, 2015115.9-3.88%
Dec 31, 2014120.6-148.43%
Dec 31, 2013-249-510.07%
Dec 31, 201260.7

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat